Evidence map›Paper›PMID 42608874›Full record

ReviewPulmonary medicine2026

Combating Drug-Resistant Tuberculosis: Advancements in Diagnostics and Therapeutics.

Silvi Gautam, Jahanvi Saini, Shabaaz Begum Jameel Pasha, Divakar Sharma, Divya Venugopal

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Silvi GautamDepartment of Microbiology, Graphic Era (Deemed to be) University, Dehradun, India, geu.ac.in.
Jahanvi SainiDepartment of Microbiology, Graphic Era (Deemed to be) University, Dehradun, India, geu.ac.in.
Shabaaz Begum Jameel PashaDepartment of Microbiology, Graphic Era (Deemed to be) University, Dehradun, India, geu.ac.in.ORCID https://orcid.org/0000-0003-4941-5517
Divakar SharmaDepartment of Biotechnology, Graphic Era (Deemed to be) University, Dehradun, India, geu.ac.in.ORCID https://orcid.org/0000-0002-8735-5562
Divya VenugopalDepartment of Microbiology, Graphic Era (Deemed to be) University, Dehradun, India, geu.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing prevalence of multidrug-resistant (MDR) and extensively drug-resistant (XDR)Mycobacterium tuberculosis has emerged as a major global health concern. Advanced molecular diagnostics, including rapid assays, have improved resistance detection; however, resource-limited settings remain underserved. Nanotechnology-based drug delivery systems, including polymeric carriers, solid lipid nanoparticles, and silver nanoparticles, can provide targeted delivery, prolonged release, and improved bioavailability. Drug repurposing strategies using existing drugs like linezolid, celecoxib, and nitazoxanide also show a promising option in combating drug-resistant TB while reducing treatment duration. Host-directed therapies (HDTs) and natural products offer complementary strategies by enhancing host immune responses and providing multitarget antimycobacterial effects. This review emphasizes the drug resistance mechanisms and advancements in novel theranostics. Despite significant progress, challenges related to cost-effective scalability, accessibility of advanced diagnostics, and optimization of therapeutic systems continue to limit clinical translation. Future research must prioritize multidisciplinary collaborations to accelerate drug development, enhance diagnostic capabilities, and expand nanotechnology-based solutions to address the TB epidemic effectively.

Indexed as

Antitubercular AgentsMycobacterium tuberculosisTuberculosis, Multidrug-ResistantDrug Delivery SystemsDrug RepositioningHost-Directed TherapyHumansNanotechnologyAntitubercular Agentsantibioticsdrug repurposingdrug resistancemutationMycobacterium tuberculosisnanotechnology

Identifiers

PMID42608874
PMCPMC13482042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.